Melanoma: Does Sequencing Really Matter?

Article Oncology

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. A. Ascierto et al.

Summary: This study is a randomized, three-arm, noncomparative phase II trial that aims to explore sequential immunotherapy and BRAF/MEK inhibition for patients with BRAFV600-mutant metastatic melanoma. The results show that sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Reinhard Dummer et al.

Summary: The COMBI-i trial evaluated the combination of spartalizumab with dabrafenib and trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma. The study did not meet its primary end point of progression-free survival, indicating that broad first-line use of this combination is not supported by the results. Further research is needed to identify patient subpopulations who may benefit from checkpoint inhibitor plus targeted therapy combinations.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Yujue Wang et al.

Summary: Rationally sequencing and combining PD-1/L1 and MAPK-targeted therapies may overcome innate and acquired resistance. Comparative analysis of different treatment regimens can optimize therapeutic efficacy for melanoma and colorectal and pancreatic carcinoma.

CANCER CELL (2021)

添加到收藏夹

Article Medicine, General & Internal